- The 22nd European Congress of Neurosurgery will take
place in Belgrade, Serbia, on
October 16-20, 2022.
- Dr. Behnam Rezai Jahromi, a
neurosurgeon from Helsinki University
Hospital, will present a case series poster, titled "Active CSF
Exchange System for IVH Treatment."
- Dr. Rezai Jahromi will also lead a live IRRAflow
educational session on Tuesday, October
18th, at 1000 CET within the
IRRAS booth in the Congress' Exhibit Hall.
STOCKHOLM, Oct. 13, 2022 /PRNewswire/ -- IRRAS, a
commercial-stage medical technology company with a comprehensive
portfolio of innovative products for neurocritical care, today
announced it will be exhibiting at EANS 2022, the 22nd European
Congress of Neurosurgery, hosted by the European Association of
Neurological Societies. After two consecutive years in which the
Congress was impacted by the Covid-19 pandemic, the EANS Annual
Congress is again being held in person in Belgrade, Serbia, on 16 to 20 October 2022. Attendees of EANS 2022 are
encouraged to learn more about IRRAS' products, including its
IRRAflow Active Fluid Exchange system, by visiting IRRAS'
booth #10.
In addition to exhibiting its products for conference
participants, clinical data regarding the use of the
IRRAflow system to treat intracerebral hemorrhage (ICH)
and intraventricular hemorrhage (IVH) will be presented in a case
series poster by Dr. Behnam Rezai
Jahromi, a neurosurgeon from Helsinki
University Hospital. The poster presentation, titled "Active
CSF Exchange System for IVH Treatment," will be available for
review, in-person and virtually, for registered participants of
EANS.
"My experience utilizing IRRAflow has shown
impressive results in clearing out toxic blood in ventricles after
patients have experienced ruptured aneurysms and the associated
intracranial hemorrhage," said Dr. Rezai Jahromi. "The combination
of the IRRAflow system's recurring irrigation, when combined
with thrombolytic medication, can change the composition of
cerebrospinal fluid, accelerate the ability to remove the toxic
materials, and improve the clinical outcomes of these critically
ill patients."
Dr. Rezai Jahromi will also lead an educational session on
Tuesday, October 18th, at
1000 CET within the IRRAS booth.
During the session, Dr. Rezai Jahromi will present his clinical
experience utilizing IRRAflow to treat IVH patients and
will also provide an update on the ARCH
(Active Removal of
Intracerebral Hematoma via active irrigation of
ventricular system) clinical trial.
To learn more about the ARCH clinical trial, click here:
https://clinicaltrials.gov/ct2/show/NCT05118997?cond=active+removal&draw=2&rank=1.
About IRRAS
IRRAS is a global medical care company focused on delivering
innovative medical solutions to improve the lives of critically ill
patients. IRRAS designs, develops, and commercializes neurocritical
care products that transform patient outcomes and decrease the
overall cost of care by addressing complications associated with
current treatment methodologies. IRRAS markets and sells its
comprehensive, innovative IRRAflow and Hummingbird ICP
Monitoring product lines to hospitals worldwide through its direct
sales organization in the United
States and select European countries as well as an
international network of distribution partners.
IRRAS maintains its headquarters in Stockholm, Sweden, with corporate offices in
Munich, Germany, and San Diego, California, USA. For more
information, please visit www.irras.com.
IRRAS is listed on Nasdaq Stockholm (ticker: IRRAS).
For more information, please contact:
Sten Gustafsson
Director, Investor Relations
sten.gustafsson@irras.com
+46 102 11 5172
The information was released for public disclosure, through
the agency of the contact person above, on October 13, 2022, at 8:30 (CET).
View original
content:https://www.prnewswire.co.uk/news-releases/irras-announces-participation-and-data-presentation-at-the-22nd-european-congress-of-neurosurgery-301648252.html
